Overactive bladder is a symptom complex that includes urinaryurgency with or without urge incontinence, urinary frequency(voiding eight or more times in a 24-hour period), and nocturia(awakening two or more times at night to void).1,2,3 The InternationalContinence Society classifies overactive bladder as a syndromefor which no precise cause has been identified, with local abnormalitiesruled out by diagnostic evaluation.4,5 This review extends beyondthe International Continence Society's current definition ofoveractive bladder, since a broader approach to this syndromeis essential for optimal management.6,7
Because overactive bladder is a recently defined syndrome, itsprevalence and natural . . . [Full Text of this Article]
Pathophysiology
Diagnostic Evaluation
Therapy
Nonpharmacologic Interventions
Drug Therapy
Summary
Source Information
From the Division of Geriatric Medicine and Gerontology, Wesley Woods Center, Center for Health in Aging, Emory University, and the Birmingham/Atlanta Veterans Affairs Geriatric Research Education Clinical Center both in Atlanta.
Address reprint requests to Dr. Ouslander at the Wesley Woods Center of Emory University, 1841 Clifton Rd., NE, Atlanta, GA 30329, or at jouslan@emory.edu.
Maruyama, S., Tsukada, H., Nishiyama, S., Kakiuchi, T., Fukumoto, D., Oku, N., Yamada, S.
(2008). In Vivo Quantitative Autoradiographic Analysis of Brain Muscarinic Receptor Occupancy by Antimuscarinic Agents for Overactive Bladder Treatment. J. Pharmacol. Exp. Ther.
325: 774-781
[Abstract][Full Text]
Burnstock, G.
(2007). Physiology and Pathophysiology of Purinergic Neurotransmission. Physiol. Rev.
87: 659-797
[Abstract][Full Text]
Treadway, A. K., Canales, A. E.
(2007). New Options and Strategies for the Treatment of Urinary Incontinence. Journal of Pharmacy Practice
20: 29-48
[Abstract]
Burnstock, G.
(2006). Pathophysiology and therapeutic potential of purinergic signaling.. Pharmacol. Rev.
58: 58-86
[Abstract][Full Text]
Dmitrieva, N., Berkley, K. J.
(2005). Influence of estradiol on micturition thresholds in the rat: involvement of the hypogastric nerve. Am. J. Physiol. Regul. Integr. Comp. Physiol.
289: R1724-R1728
[Abstract][Full Text]
Holt, J. D. S., Watson, M. J., Chang, J. P., O'Neill, S. J., Wei, K., Pendergast, W., Gengo, P. J., Chang, K.-J.
(2005). DPI-221 [4-(({alpha}-S)-{alpha}-((2S,5R)-2,5-Dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide]: A Novel Nonpeptide {delta} Receptor Agonist Producing Increased Micturition Interval in Normal Rats. J. Pharmacol. Exp. Ther.
315: 601-608
[Abstract][Full Text]
Ruby, C. M., Hanlon, J. T., Fillenbaum, G. G., Pieper, C. F., Branch, L. G., Bump, R. C.
(2005). Medication Use and Control of Urination Among Community-Dwelling Older Adults. J Aging Health
17: 661-674
[Abstract]
Thorneloe, K. S., Meredith, A. L., Knorn, A. M., Aldrich, R. W., Nelson, M. T.
(2005). Urodynamic properties and neurotransmitter dependence of urinary bladder contractility in the BK channel deletion model of overactive bladder. Am. J. Physiol. Renal Physiol.
289: F604-F610
[Abstract][Full Text]
Verhamme, K. M. C., Dieleman, J. P., Van Wijk, M. A. M., van der Lei, J., Bosch, J. L. H. R., Stricker, B. H. C., Sturkenboom, M. C. J. M.
(2005). Nonsteroidal Anti-inflammatory Drugs and Increased Risk of Acute Urinary Retention. Arch Intern Med
165: 1547-1551
[Abstract][Full Text]
Emmons, S. L., Otto, L.
(2005). Acupuncture for Overactive Bladder: A Randomized Controlled Trial. Obstet Gynecol
106: 138-143
[Abstract][Full Text]
Gill, S. S., Mamdani, M., Rochon, P. A.
(2004). Management of Overactive Bladder. NEJM
350: 2213-2213
[Full Text]